ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments
November 23, 2021On November 17, 2021, Simcere Pharmaceutical Group Limited (2096.HK) announced that the company has reached collaboration agreement with the Shanghai Institute of Materia Medica (SIMM)... -
Amgen, Simcere to Co-Develop and Commercialize Biosimilars in China
September 28, 2017Amgen and Simcere Pharmaceutical Group announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. -
Amgen and Simcere announce strategic collaboration to co-develop and commercialize biosimilars in Ch
September 28, 2017Amgen (NASDAQ: AMGN) and Simcere Pharmaceutical Group have announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. -
Simcere, Amgen to bring in 4 biosimilars to China
September 28, 2017Amgen will remain responsible for the co-development, marketing approval applications and manufacturing of the biosimilars. Simcere will be responsible for distribution and commercialization in China
Pharma Sources Insight January 2025
